Abalonex, LLC
🇺🇸United States
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain Injury
Phase 2
Not yet recruiting
- Conditions
- Traumatic Brain InjuryCerebral Edema
- Interventions
- Drug: ABX-101 1mgDrug: ABX-101 2mg
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Abalonex, LLC
- Target Recruit Count
- 45
- Registration Number
- NCT06096415
News
No news found